Clavis Pharma: Clinical Trials

11 trials sponsored by Clavis Pharma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

11 completed. 7 Phase 2, 5 Phase 1, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 27Completed 7
Phase 15Completed 5
Phase 31Completed 1

Follow Clavis Pharma: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Elacytarabine Mass Balance Study in Healthy Volunteers
[14C]-Elacytarabine - Not Applicable as This is a Mass Balance/Pharmacokinetic Study Performed in Healthy Subjects
Phase 1CompletedClavis Pharma62013-02-012013-08-28
The Pharmacokinetics and Cardiac Properties of Elacytarabine (CP-4055)
Elacytarabine for infusion - Relapsed/Refractory AML
Phase 1CompletedClavis Pharma432010-10-012013-09-23
Study of Elacytarabine Versus Investigator's Choice in Patients With Late Stage Acute Myeloid Leukaemia (AML)
Elacytarabine, Investigator's Choice - Acute Myeloid Leukemia (AML)
Phase 3CompletedClavis Pharma3812010-06-012013-09-27
A Study of Elacytarabine (CP-4055) Plus Idarubicin as Second Course Remission-Induction Therapy in Patients With Acute Myeloid Leukaemia
Elacytarabine plus idarubicin - Acute Myeloid Leukemia
Phase 2CompletedClavis Pharma512009-12-012013-09-27
A Study of CP-4126 in Patients With Advanced Pancreatic Cancer
IV CP-4126 - Advanced Adenocarcinoma of Pancreas
Phase 2CompletedClavis Pharma212009-04-012012-02-10
A Phase I Clinical Study of Oral CP-4126 in Patients With Advanced Solid Tumour
CP-4126, Gemcitabine - Solid Tumors
Phase 1CompletedClavis Pharma262008-10-012010-09-06
A Phase I/II Study of CP-4055 in Patients With Platinum Resistant Ovarian Cancer
CP-4055 - Ovarian Cancer
Phase 1 / Phase 2CompletedClavis Pharma282008-04-012013-09-13
A Phase II Study of CP-4055 as Second Line Therapy in Patients With Advanced Colorectal Cancer
CP-4055 - Advanced Colorectal Cancer, Colorectal Cancer
Phase 2CompletedClavis Pharma162007-05-012009-06-04
Multicentre, Dose Finding, Ph II,CP-4055 in Comb. With Sorafenib - Patients With Metastatic Malignant Melanoma
CP-4055, Sorafenib (Nexavar) - Malignant Melanoma
Phase 2CompletedClavis Pharma182007-03-012013-09-12
A Phase I/II Study of CP-4055 in Patients With Refractory/Relapsed Hematologic Malignancies
CP-4055 - Hematologic Malignancies, AML
Phase 1 / Phase 2CompletedClavis Pharma1532006-05-012013-09-18
Clinical Study of Previously Untreated Patients With Malignant Melanoma
CP-4055 (ELACYT) - Malignant Melanoma, Neoplasm Metastasis
Phase 2CompletedClavis Pharma422005-09-012007-07-10

Conditions studied

Neoplasms (6)  ·  Neoplasm Metastasis (4)  ·  Leukemia, Myeloid, Acute (3)  ·  Melanoma (2)  ·  Colorectal Neoplasms (1)  ·  Hematologic Neoplasms (1)  ·  Leukemia (1)  ·  Ovarian Neoplasms (1)  ·  Recurrence (1)

Interventions

5'-oleoyl cytarabine (9)  ·  CP 4126 (2)  ·  Gemcitabine (1)  ·  Idarubicin (1)  ·  Sorafenib (1)

Countries

Norway (6)  ·  United Kingdom (5)  ·  United States (5)  ·  Belgium (4)  ·  France (3)  ·  Germany (3)  ·  Italy (3)  ·  Spain (2)  ·  Sweden (2)  ·  Australia (1)  ·  Canada (1)  ·  Ireland (1)  ·  Netherlands (1)  ·  Poland (1)  ·  Romania (1)

Top investigators

Ahmad H Awada, MD (1)  ·  David A Rizzieri, MD (1)  ·  David Rizzieri, MD (1)  ·  Francis J Giles, MD (1)  ·  Francis J Giles, MD, PhD (1)  ·  Jim Cassidy, MBChB, MD (1)  ·  Sandro Pignata, MD (1)  ·  Steven Knapper, MD (1)  ·  Svein Dueland, MD (1)  ·  Svein Dueland, MD, Ph.D (1)

Results publications

PMID 23345000, PMID 24433865, PMID 24841975